All In Biotech

Drug Trial Radar · NCT01559077

Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Mar 2012

Primary completion

Jun 2012

Study completion Nov 2012

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Mar 21, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-TTR02 in healthy volunteer subjects.

Conditions

  • TTR-mediated Amyloidosis

Interventions

  • ALN-TTR02Drug

    Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion

  • Sterile Normal Saline (0.9% NaCl)Drug

    Calculated volume to match active comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation.Time frame: Up to 28 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    Leeds, United Kingdom

  • Clinical Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.